The first proof-of-concept study that demonstrated CMV’s efficacy as a cancer vaccine utilized MCMV-based vaccines expressing human prostate-specific antigen (PSA) for prostate cancer immunotherapy [92]. The gene discussed is KLK3; the disease is Familial prostate cancer.